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Background
Around 6–8% of patients with HIV infection are co-
infected with hepatitis B virus (HBV) in the Western
world. At least 10% of them are superinfected by hepatitis
delta virus (HDV). The impact of HIV on liver fibrosis pro-
gression in patients with HBV or HDV chronic hepatitis in
the HAART era is still uncertain.
Methods
A retrospective case-control study was conducted at our
institution comparing the progression of liver fibrosis in
patients with HBV or HDV with and without HIV co-infec-
tion. Clinical and laboratory outcomes were recorded.
Liver fibrosis was measured by transient elastometry
(FibroScan®) and by FIB-4. Values of FibroScan above 9.5
kPa and values over 3.25 for FIB-4 were considered as
diagnostic of advanced liver fibrosis (F3–F4 Metavir score
estimates). Patients with positive serum HCV-RNA were
excluded from this analysis.
Summary of results
A total of 26 HDV-infected patients were included in the
study, 16 HIV-positive as cases and 10 HIV-negative as
controls. Median follow-up was 4 years (3–5). Main
demographics: mean age 43/40 years and 68.4%/31.4%
males, respectively. Advanced liver fibrosis was recog-
nized in 40% of cases in both groups using FibroScan. It
was 43% and 57%, respectively, using FIB-4 (p = 0.38).
HDV genotype D and A were the most prevalent in both
groups, without significant differences in prevalence rates.
Although mean time of HBV infection and mean serum
HDV-RNA levels were similar in both groups (19 vs. 18
years, p = 0.7; 13 vs. 9 log10, p = 0.6), hepatic decompen-
sation events occurred more frequently in HIV-negative
than HIV-positive patients (6 vs. 2, p = 0.08). Two HIV-
positive patients were lost to follow-up and one died from
lymphoma. All HIV-HDV co-infected patients were under
tenofovir-containing HAART regimens, while only 4/10
patients in the control group had received any treatment
(interferon) during the study period.
Conclusion
The prognosis of chronic hepatitis delta seems to be worst
in HIV-negative individuals than in HIV co-infected
patients on antiretroviral therapy. Inhibition of HBV rep-
lication by using tenofovir might indirectly ameliorate
delta pathogenicity.
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